GIPR and obesity due to melanocortin 4 receptor deficiency: The treatment of obesity has been transformed by the food and drug administration approval of incretin‐based therapies (i.e., those targeting glucagon‐like peptide 1 (GLP‐1) and gastric inhibitory polypeptide receptors) for the treatment of obesity.